Background & Aims: Increased concentrations of tumor necrosis factor (TNF), a potent
proinflammatory cytokine, can be shown in the mucosa of patients with active Crohn's …

Background Studies in animals and an open-label trial have suggested a role for antibodies
to tumor necrosis factor α, specifically chimeric monoclonal antibody cA2, in the treatment of …

Antibodies to tumor necrosis factor (TNF)‐α have been recently proposed as effective
treatment for patients with Crohn's disease. Here, we analyze the functional role of TNF‐α in …

Background Adalimumab (ADA) and certolizumab pegol (CZP) have demonstrated efficacy
in Crohn's disease (CD) patients previously treated with infliximab (IFX). Aim To assess the …

BACKGROUND & AIMS: Anti–tumor necrosis factor (TNF) α antibodies are effective in
treating patients with Crohn's disease whereas soluble TNFα receptors have not shown …

Background & Aims: Tumor necrosis factor blockade has been shown to be an effective
treatment strategy in Crohn's disease (CD). Adalimumab is a human immunoglobulin G1 …

Background: Monoclonal antibodies to the pro‐inflammatory cytokine tumour necrosis factor‐
α have shown efficacy in treating Crohn's disease, but can be immunogenic. Soluble tumour …

Anti-tumor necrosis factor (TNF) antibodies are successfully used in the therapy of
inflammatory bowel diseases (IBD). However, the molecular mechanism of action of these …

Background: CDP870 is a PEGylated Fab′ fragment of a humanized monoclonal antibody
that neutralizes tumour necrosis factor‐α. Aim: To evaluate the safety and efficacy of a single …

Background & Aims: Tumor necrosis factor (TNF) is a pivotal cytokine in intestinal
inflammation. Controlled trials using a chimeric anti-TNF antibody (infliximab) have shown …